Entry Point Capital, LLC Arcutis Biotherapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 6,572 shares of ARQT stock, worth $70,123. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,572Holding current value
$70,123% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
127MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$123 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$107 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$105 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$93.7 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$92 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $642M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...